REG - Allergy Therapeutics - Nick Wykeman to step down as CFO

Allergy TherapeuticsAnnouncement

26/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220526:nRSZ8441Ma&default-theme=true

RNS Number : 8441M  Allergy Therapeutics PLC  26 May 2022

Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

 

Allergy Therapeutics announces that Nick Wykeman is to step down as Chief
Financial Officer

 

 

26 May 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy vaccines, today
announces that Nick Wykeman, Chief Financial Officer and Board Director, aged
57, has tendered his resignation, with effect from 30 November 2022, in order
to pursue non-executive roles.

 

Nick Wykeman, who has been a Director of Allergy Therapeutics for six years,
remains in his role for six months and a search for his successor will now
commence.

 

Manuel Llobet, Chief Executive Officer, commented: "We are very sorry that
Nick Wykeman has decided to leave the Company after a successful period with
the business but fully understand his decision. I should like to take this
opportunity to thank him for his dedication and insight over the past six
years and look forward to his replacement joining the Group."

 

Nick Wykeman, Chief Financial Officer, added: "It has been a privilege to
serve as Allergy Therapeutics' Chief Financial Officer over the past six years
and I wish the Company and its employees continued success in the future. I
will remain focused on the role over the coming months and ensure an orderly
handover to my successor."

 

- ENDS -

 

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

 

Panmure Gordon (Nominated Adviser and Broker)

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com (mailto:christina@sternir.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company
focussed on the treatment and diagnosis of allergic disorders, including
aluminium free immunotherapy vaccines that have the potential to cure disease.
The Group sells proprietary and third-party products from its subsidiaries in
nine major European countries and via distribution agreements in an additional
ten countries. Its broad pipeline of products in clinical development includes
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art
MHRA-approved manufacturing facilities and laboratories. The Group, which has
achieved over 9% compound annual growth since formation, employs c.600
employees and is listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBKPBQCBKDCPB